AU2008222663B2 - Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell - Google Patents
Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell Download PDFInfo
- Publication number
- AU2008222663B2 AU2008222663B2 AU2008222663A AU2008222663A AU2008222663B2 AU 2008222663 B2 AU2008222663 B2 AU 2008222663B2 AU 2008222663 A AU2008222663 A AU 2008222663A AU 2008222663 A AU2008222663 A AU 2008222663A AU 2008222663 B2 AU2008222663 B2 AU 2008222663B2
- Authority
- AU
- Australia
- Prior art keywords
- rna
- cell
- region
- expression
- coding region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 202
- 238000000034 method Methods 0.000 title claims abstract description 99
- 230000002829 reductive effect Effects 0.000 title description 12
- 230000003013 cytotoxicity Effects 0.000 title description 9
- 231100000135 cytotoxicity Toxicity 0.000 title description 9
- 230000000840 anti-viral effect Effects 0.000 title description 3
- 230000001177 retroviral effect Effects 0.000 claims abstract description 86
- 108091032955 Bacterial small RNA Proteins 0.000 claims abstract description 25
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 25
- 241000713666 Lentivirus Species 0.000 claims abstract description 14
- 230000002222 downregulating effect Effects 0.000 claims abstract description 7
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims abstract 6
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims abstract 6
- 210000004027 cell Anatomy 0.000 claims description 325
- 108090000623 proteins and genes Proteins 0.000 claims description 171
- 108091026890 Coding region Proteins 0.000 claims description 136
- 241000700605 Viruses Species 0.000 claims description 101
- 230000003612 virological effect Effects 0.000 claims description 65
- 238000004806 packaging method and process Methods 0.000 claims description 61
- 239000002773 nucleotide Substances 0.000 claims description 49
- 241001430294 unidentified retrovirus Species 0.000 claims description 49
- 125000003729 nucleotide group Chemical group 0.000 claims description 48
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 45
- 102000014450 RNA Polymerase III Human genes 0.000 claims description 38
- 108010078067 RNA Polymerase III Proteins 0.000 claims description 38
- 230000000692 anti-sense effect Effects 0.000 claims description 32
- 230000000295 complement effect Effects 0.000 claims description 27
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 25
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 25
- 210000000130 stem cell Anatomy 0.000 claims description 19
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 18
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 15
- 108700026244 Open Reading Frames Proteins 0.000 claims description 15
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 13
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 10
- 230000003828 downregulation Effects 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- 239000004098 Tetracycline Substances 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 8
- 229960002180 tetracycline Drugs 0.000 claims description 8
- 229930101283 tetracycline Natural products 0.000 claims description 8
- 235000019364 tetracycline Nutrition 0.000 claims description 8
- 150000003522 tetracyclines Chemical class 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 7
- 241001529936 Murinae Species 0.000 claims description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 5
- 210000004748 cultured cell Anatomy 0.000 claims description 5
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 4
- 241001492404 Woodchuck hepatitis virus Species 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 3
- 239000003184 complementary RNA Substances 0.000 claims description 3
- 102100021696 Syncytin-1 Human genes 0.000 claims 2
- 239000013598 vector Substances 0.000 abstract description 99
- 239000004055 small Interfering RNA Substances 0.000 abstract description 86
- 230000000694 effects Effects 0.000 abstract description 39
- 231100000065 noncytotoxic Toxicity 0.000 abstract description 9
- 230000002020 noncytotoxic effect Effects 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 124
- 108091027967 Small hairpin RNA Proteins 0.000 description 92
- 241000725303 Human immunodeficiency virus Species 0.000 description 58
- 241001465754 Metazoa Species 0.000 description 53
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 49
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 49
- 239000005090 green fluorescent protein Substances 0.000 description 49
- 239000013612 plasmid Substances 0.000 description 44
- 108020004414 DNA Proteins 0.000 description 40
- 101150066555 lacZ gene Proteins 0.000 description 40
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 34
- 210000004698 lymphocyte Anatomy 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 31
- 238000000684 flow cytometry Methods 0.000 description 26
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 23
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 23
- 230000009368 gene silencing by RNA Effects 0.000 description 23
- 239000002245 particle Substances 0.000 description 23
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 22
- 241000713311 Simian immunodeficiency virus Species 0.000 description 22
- 102000048160 human CCR5 Human genes 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 20
- 230000001717 pathogenic effect Effects 0.000 description 19
- 230000001413 cellular effect Effects 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 101000897431 Macaca mulatta C-C chemokine receptor type 5 Proteins 0.000 description 17
- 239000003623 enhancer Substances 0.000 description 17
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 16
- 210000005259 peripheral blood Anatomy 0.000 description 16
- 239000011886 peripheral blood Substances 0.000 description 16
- 238000010361 transduction Methods 0.000 description 16
- 230000026683 transduction Effects 0.000 description 16
- 239000003550 marker Substances 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 230000001105 regulatory effect Effects 0.000 description 15
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 14
- 108700008625 Reporter Genes Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 238000013518 transcription Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 108700019146 Transgenes Proteins 0.000 description 13
- 101710091045 Envelope protein Proteins 0.000 description 11
- 241000282560 Macaca mulatta Species 0.000 description 11
- 101710188315 Protein X Proteins 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000002308 embryonic cell Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000009261 transgenic effect Effects 0.000 description 8
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 7
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 7
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229960003722 doxycycline Drugs 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108010061299 CXCR4 Receptors Proteins 0.000 description 6
- 102000012000 CXCR4 Receptors Human genes 0.000 description 6
- 108090000331 Firefly luciferases Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 102000008935 SMN Complex Proteins Human genes 0.000 description 6
- 108010049037 SMN Complex Proteins Proteins 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 108010067390 Viral Proteins Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 238000011124 ex vivo culture Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102400001093 PAK-2p27 Human genes 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 108700005077 Viral Genes Proteins 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 108091081021 Sense strand Proteins 0.000 description 4
- 108090000848 Ubiquitin Proteins 0.000 description 4
- 102000044159 Ubiquitin Human genes 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108700004030 rev Genes Proteins 0.000 description 4
- 101150098213 rev gene Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 102000008682 Argonaute Proteins Human genes 0.000 description 3
- 108010088141 Argonaute Proteins Proteins 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 108010060424 DEAD Box Protein 20 Proteins 0.000 description 3
- 102000008167 DEAD Box Protein 20 Human genes 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 208000032274 Encephalopathy Diseases 0.000 description 3
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000713800 Feline immunodeficiency virus Species 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 3
- 101001126084 Homo sapiens Piwi-like protein 2 Proteins 0.000 description 3
- 101001001560 Homo sapiens Piwi-like protein 4 Proteins 0.000 description 3
- 101000690503 Homo sapiens Protein argonaute-3 Proteins 0.000 description 3
- 101000690460 Homo sapiens Protein argonaute-4 Proteins 0.000 description 3
- 241000283923 Marmota monax Species 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100029365 Piwi-like protein 2 Human genes 0.000 description 3
- 102100036145 Piwi-like protein 4 Human genes 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 102100026791 Protein argonaute-3 Human genes 0.000 description 3
- 102100026800 Protein argonaute-4 Human genes 0.000 description 3
- 101000780661 Rattus norvegicus Protein argonaute-2 Proteins 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 108700026226 TATA Box Proteins 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000012212 insulator Substances 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000007502 viral entry Effects 0.000 description 3
- 230000017613 viral reproduction Effects 0.000 description 3
- 210000004340 zona pellucida Anatomy 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- -1 CAR Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 description 2
- 101000780643 Homo sapiens Protein argonaute-2 Proteins 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 101150101095 Mmp12 gene Proteins 0.000 description 2
- 101100240347 Mus musculus Nectin2 gene Proteins 0.000 description 2
- 102100023064 Nectin-1 Human genes 0.000 description 2
- 101710043845 Nectin-1 Proteins 0.000 description 2
- 102100035488 Nectin-2 Human genes 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102100029740 Poliovirus receptor Human genes 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 102100034207 Protein argonaute-2 Human genes 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000000408 embryogenic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 101150098622 gag gene Proteins 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000010468 interferon response Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000005758 transcription activity Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 230000006648 viral gene expression Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 102000004274 CCR5 Receptors Human genes 0.000 description 1
- 108010017088 CCR5 Receptors Proteins 0.000 description 1
- 101150017501 CCR5 gene Proteins 0.000 description 1
- 101150066398 CXCR4 gene Proteins 0.000 description 1
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 206010019773 Hepatitis G Diseases 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241001529934 Simian T-lymphotropic virus 3 Species 0.000 description 1
- 108010071811 Simian immunodeficiency virus Gag protein p27 Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 241001365914 Taira Species 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 1
- 108010056354 Ubiquitin C Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 108010062490 p27 antigen Proteins 0.000 description 1
- INFDPOAKFNIJBF-UHFFFAOYSA-N paraquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 INFDPOAKFNIJBF-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 238000003322 phosphorimaging Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000010469 pro-virus integration Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 208000021160 simian immunodeficiency virus infection Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 101150061166 tetR gene Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/609—Vectors comprising as targeting moiety peptide derived from defined protein from viruses positive strand RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/683,962 US7737124B2 (en) | 2001-09-13 | 2007-03-08 | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
| US11/683,962 | 2007-03-08 | ||
| PCT/US2008/056245 WO2008109837A2 (en) | 2007-03-08 | 2008-03-07 | Method for expression of small antiviral rna molecules with reduced cytotoxicity within a cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008222663A1 AU2008222663A1 (en) | 2008-09-12 |
| AU2008222663B2 true AU2008222663B2 (en) | 2013-09-05 |
Family
ID=39816837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008222663A Ceased AU2008222663B2 (en) | 2007-03-08 | 2008-03-07 | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US7737124B2 (enExample) |
| EP (1) | EP2115164B1 (enExample) |
| JP (1) | JP5399927B2 (enExample) |
| AU (1) | AU2008222663B2 (enExample) |
| CA (2) | CA3012986A1 (enExample) |
| WO (1) | WO2008109837A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7737124B2 (en) * | 2001-09-13 | 2010-06-15 | California Institute Of Technology | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
| AU2002326906C1 (en) * | 2001-09-13 | 2009-01-29 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
| EP1451316B1 (en) | 2001-09-13 | 2014-08-06 | California Institute Of Technology | Method for producing transgenic birds |
| GB2421948A (en) * | 2004-12-30 | 2006-07-12 | Ist Superiore Sanita | Retrotransposon inhibition to treat cancer |
| AU2006252406B2 (en) | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| SG173337A1 (en) | 2006-07-21 | 2011-08-29 | California Inst Of Techn | Targeted gene delivery for dendritic cell vaccination |
| EP2166107A1 (en) * | 2008-09-12 | 2010-03-24 | TaconicArtemis GmbH | Lentiviral vectors for the expression of shRNA |
| WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| EP2425001A4 (en) * | 2009-04-30 | 2012-11-14 | Univ California | ANTI-HIV COMBINATION VECTORS, TARGETING VECTORS AND METHOD OF USE |
| DK3329772T3 (da) * | 2009-07-15 | 2020-01-27 | Calimmune Inc | Dobbeltvektor til inhibering af human immundefektvirus |
| WO2011011584A1 (en) | 2009-07-24 | 2011-01-27 | Immune Design Corp | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
| EP2831095B1 (en) | 2012-03-30 | 2018-11-28 | Immune Design Corp. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign |
| US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| CN104119285B (zh) * | 2013-04-28 | 2016-06-29 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| EP3027755B1 (en) | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| CN108026543A (zh) * | 2015-05-18 | 2018-05-11 | 卡琳缪恩股份有限公司 | 用于hiv的治疗的基因疗法及其用途 |
| EP3319631A4 (en) * | 2015-07-08 | 2019-01-09 | American Gene Technologies International Inc. | HIV PREMUNICATION AND IMMUNOTHERAPY |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| CA3011529A1 (en) | 2016-01-15 | 2017-07-20 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta t-cells |
| US10888613B2 (en) * | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
| JP6975465B2 (ja) * | 2016-02-19 | 2021-12-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | 遺伝子改変細胞をポジティブに選択して、排除するための短ヘアピンｒｎａ（ｓｈｒｎａ７３４）およびその使用 |
| ES2911448T3 (es) | 2016-03-09 | 2022-05-19 | American Gene Tech Int Inc | Vectores combinados y métodos para el tratamiento del cáncer |
| EP3468617A4 (en) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS |
| IL300730A (en) | 2016-07-08 | 2023-04-01 | American Gene Tech Int Inc | Pre-HIV vaccine and immunotherapy |
| JP7176756B2 (ja) | 2016-07-21 | 2022-11-22 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | パーキンソン病を処置するためのウイルスベクター |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| AU2018367546B2 (en) * | 2017-11-15 | 2024-07-18 | Weird Science Llc | Methods and compositions for non-myeloablative bone marrow reconstitution |
| WO2020097049A1 (en) | 2018-11-05 | 2020-05-14 | American Gene Technologies International Inc. | Vector system for expressing regulatory rna |
| US20250057884A1 (en) * | 2021-12-31 | 2025-02-20 | Beijing Solobio Genetechnology Co. , Ltd. | Chimeric Antigen Receptor-T Cells Targeting HIV-Infected Cells |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096536A (en) * | 1990-07-06 | 2000-08-01 | University Of New Mexico | In vitro cell culture in media containing beta-alanyl-taurine or carbobenzoxy beta-alanyl-taurine |
| US5258289A (en) | 1990-09-05 | 1993-11-02 | Davis Claude G | Method for the selecting of genes encoding catalytic antibodies |
| US6664107B1 (en) * | 1993-05-26 | 2003-12-16 | Ontario Cancer Institute, University Health Network | CD45 disrupted nucleic acid |
| US5859310A (en) | 1993-06-14 | 1999-01-12 | Basf Aktiengesellschaft | Mice transgenic for a tetracycline-controlled transcriptional activator |
| IT1261847B (it) * | 1993-09-01 | 1996-06-03 | San Romanello Centro Fond | Metodo per marcare cellule eucariote. |
| US5631359A (en) * | 1994-10-11 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | Hairpin ribozymes |
| US5958713A (en) * | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
| US5650309A (en) | 1995-05-16 | 1997-07-22 | The Regents Of The University Of California | Viral vectors |
| GB9510272D0 (en) | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
| US5883081A (en) | 1995-07-26 | 1999-03-16 | The Regents Of The University Of California | Isolation of novel HIV-2 proviruses |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US20030143204A1 (en) * | 2001-07-27 | 2003-07-31 | Lewis David L. | Inhibition of RNA function by delivery of inhibitors to animal cells |
| US6255071B1 (en) | 1996-09-20 | 2001-07-03 | Cold Spring Harbor Laboratory | Mammalian viral vectors and their uses |
| DE19651443A1 (de) | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
| AU8828598A (en) * | 1997-08-15 | 1999-03-08 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6100087A (en) * | 1998-03-11 | 2000-08-08 | City Of Hope | Ribozymes targeted to human CCR5 mRNA |
| US6060317A (en) * | 1998-08-11 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Method of transducing mammalian cells, and products related thereto |
| JP2002532058A (ja) * | 1998-08-20 | 2002-10-02 | セル ジェネシス インコーポレイテッド | 組換え遺伝子産物の産生の間の細胞傷害性を調節するためのサプレッサーｔＲＮＡの使用 |
| US6274788B1 (en) | 1998-09-23 | 2001-08-14 | International Centre For Genetic Engineering And Biotechnology | Bicistronic DNA construct comprising X-myc transgene for use in production of transgenic animal model systems for human hepatocellular carcinoma and transgenic animal model systems so produced |
| US6312956B1 (en) * | 1999-10-01 | 2001-11-06 | Vanderbilt University | Nuclear targeted peptide nucleic acid oligomer |
| AU1333401A (en) * | 1999-10-15 | 2001-04-30 | Ohio State University Research Foundation, The | Methods for analyzing the insertion capabilities of modified group ii introns |
| US6218186B1 (en) * | 1999-11-12 | 2001-04-17 | Trustees Of The University Of Pennsylvania | HIV-MSCV hybrid viral vector for gene transfer |
| US20030084471A1 (en) * | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
| EP1390472A4 (en) | 2001-05-29 | 2004-11-17 | Sirna Therapeutics Inc | NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS |
| WO2003006691A1 (en) | 2001-07-10 | 2003-01-23 | Johnson & Johnson Research Pty Limited | Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| US20030219823A1 (en) | 2001-09-07 | 2003-11-27 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| AU2002326906C1 (en) * | 2001-09-13 | 2009-01-29 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
| US7195916B2 (en) * | 2001-09-13 | 2007-03-27 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
| US7737124B2 (en) | 2001-09-13 | 2010-06-15 | California Institute Of Technology | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
| EP2000160A3 (en) * | 2002-10-30 | 2009-03-11 | Gambro Lundia AB | Method and apparatuses for determining the efficiency of dialysis |
| US20050221354A1 (en) * | 2004-02-18 | 2005-10-06 | Wyeth | Nucleic acid arrays for monitoring expression profiles of drug target genes |
-
2007
- 2007-03-08 US US11/683,962 patent/US7737124B2/en not_active Expired - Lifetime
-
2008
- 2008-03-07 EP EP08731694.9A patent/EP2115164B1/en not_active Not-in-force
- 2008-03-07 CA CA3012986A patent/CA3012986A1/en not_active Abandoned
- 2008-03-07 WO PCT/US2008/056245 patent/WO2008109837A2/en not_active Ceased
- 2008-03-07 CA CA2680129A patent/CA2680129C/en active Active
- 2008-03-07 AU AU2008222663A patent/AU2008222663B2/en not_active Ceased
- 2008-03-07 JP JP2009552911A patent/JP5399927B2/ja not_active Expired - Fee Related
-
2010
- 2010-04-28 US US12/769,157 patent/US8361982B2/en not_active Expired - Fee Related
-
2013
- 2013-01-24 US US13/749,319 patent/US9034577B2/en not_active Expired - Lifetime
-
2015
- 2015-04-24 US US14/695,462 patent/US9567592B2/en not_active Expired - Fee Related
-
2016
- 2016-12-30 US US15/395,348 patent/US10041072B2/en not_active Expired - Lifetime
-
2018
- 2018-07-05 US US16/028,262 patent/US10876118B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| An, D.S. et al., Molecular Therapy. 2006 vol. 14 no. 4 pages 494-504 * |
| Qin, X-F. et al., Proceedings of the National Academy of Sciences. 2003 vol. 100 no. 1 pages 183-188 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2115164B1 (en) | 2013-08-21 |
| EP2115164A4 (en) | 2011-01-19 |
| US20150218564A1 (en) | 2015-08-06 |
| CA2680129C (en) | 2018-09-11 |
| EP2115164A2 (en) | 2009-11-11 |
| US20100267146A1 (en) | 2010-10-21 |
| WO2008109837A3 (en) | 2008-11-13 |
| JP2010520757A (ja) | 2010-06-17 |
| US8361982B2 (en) | 2013-01-29 |
| JP5399927B2 (ja) | 2014-01-29 |
| US20170107519A1 (en) | 2017-04-20 |
| US9567592B2 (en) | 2017-02-14 |
| AU2008222663A1 (en) | 2008-09-12 |
| WO2008109837A2 (en) | 2008-09-12 |
| US10041072B2 (en) | 2018-08-07 |
| US10876118B2 (en) | 2020-12-29 |
| US20190002883A1 (en) | 2019-01-03 |
| US20130295615A1 (en) | 2013-11-07 |
| CA3012986A1 (en) | 2008-09-12 |
| US20080003682A1 (en) | 2008-01-03 |
| US7737124B2 (en) | 2010-06-15 |
| CA2680129A1 (en) | 2008-09-12 |
| US9034577B2 (en) | 2015-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10876118B2 (en) | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell | |
| US7732207B2 (en) | Method for expression of small antiviral RNA molecules within a cell | |
| CA2867981C (en) | Method for expression of small antiviral rna molecules within a cell | |
| US7195916B2 (en) | Method for expression of small antiviral RNA molecules within a cell | |
| AU2002326906A1 (en) | Method for expression of small antiviral RNA molecules within a cell | |
| AU2002326907A1 (en) | Method for expression of small RNA molecules within a cell | |
| Trobridge et al. | Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection | |
| RU2426788C1 (ru) | Генетические конструкции для антивич-терапии | |
| RU2533817C1 (ru) | Усовершенствование генетических конструкций для повышения эффективности антивич терапии | |
| Trobridge et al. | Protection of Stem Cell-Derived Lymphocytes in a Primate AIDS Gene Therapy Model | |
| HK1234603A1 (en) | Method for expression of small rna molecules within a cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |